Autopsy report · NCT04916236
Combination Therapy of RMC-4630 and LY3214996 in Metastatic KRAS Mutant Cancers
Cause of deathSafety
“Due to a lack of safety and efficacy.”
Life of this trial
- Registered 11 months before it started.
- Ran for about 2 years 4 months before it stopped.
- 24 participants enrolled.
- No results are posted on the registry.
Vital statistics
- Status
- Terminated
- Phase
- Phase 1
- Sponsor
- The Netherlands Cancer Institute
- Sponsor type
- University, hospital or other
- Conditions
- Pancreatic Cancer; Colorectal Cancer; Non-small Cell Lung Cancer; KRAS Mutation-Related Tumors
- Interventions
- RMC-4630; LY3214996
- Participants
- 24
- Sites
- 1
- Countries
- Netherlands
Trials that died the same way
- Study of ADI-PEG 20 or Placebo Plus Gem and Doc in Previously Treated Subjects With Leiomyosarcoma (ARGSARC)
“Lack of Efficacy, no safety concern.” - Proof-of-concept Study of NSAID Hydrogel Patch in Treatment of Acute Pain
“Due to lack of patients number” - A Study to Evaluate Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of Natalizumab (BG00002) Administered Subcutaneously to Japanese Participants With Relapsing-Remitting Multiple Sclerosis
“Due to sponsor decision, not for efficacy or safety reasons.” - ARD-101 for Treatment of PWS: The Hunger Elimination or Reduction Objective Trial
“Due to operational and regulatory considerations.” - Randomized Trial of Image -Guided Stereotactic Radiation Therapy (IG-SRT) in Prostate Cancer
“Lack of patient accruals.”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.